Hypofractionated radiotherapy beats conventionally fractionated RT in orthotopic ATC model
TUESDAY, May 29, 2018 (HealthDay News) — In an orthotopic anaplastic thyroid cancer (ATC) model, hypofractionated radiotherapy (RT) is superior to conventionally fractionated RT, according to a study published online May 18 in Thyroid.
Ayman Oweida, Ph.D., from the University of Colorado Denver, and colleagues characterized the cellular response to radiation in a panel of ATC cell lines and tested alternative radiotherapy fractionation schedules.
The researchers found that the levels of CXCR4 were higher in radio-resistant than radio-sensitive cell lines. In an orthotopic ATC tumor model, hypofractionated RT resulted in significantly improved tumor growth delay, decreased regional and distant metastases, and improved overall survival compared with conventionally fractionated RT.
“Our findings demonstrate the heterogeneity of response to radiation in ATC tumors and superiority of hypofractionated RT in improving local control, metastatic spread, and survival in preclinical models,” the authors write. “These data support the design of clinical trials targeting radio-resistant pathways in combination with hypofractionated RT.”
Abstract/Full Text (subscription or payment may be required)
Copyright © 2018 HealthDay. All rights reserved.
